Live
- ‘Pushpa-2: The Rule’ creates nationwide buzz with electrifying updates
- CERT-In Warns iPhone Users: Update to iOS 18.1.1 Now to Avoid Hacking
- Rana Daggubati’s Show gets huge applause at 55th IFFI
- Jana Sena MLA Pulaparthi Ramanjaneyulu Elected as PAC chairman
- Stage set for counting of votes for Jharkhand Assembly elections
- MLA Sri Ganesh Engages ASHA Workers and Resource Persons in Caste Census Meeting
- Supreme Court verdict on validity of Preamble modification in 1976 likely on November 25
- ‘Zebra’ movie review: A gripping tale of banking fraud and redemption
- Saurabh Netravalkar, Unmukt Chand, Dwayne Smith and Rahkeem Cornwall headline USPL
- NPP asks members not to attend meeting called by Biren govt
Clinical trials underway on gene editing as potential therapy for sickle cell disease
As traditional treatments such as blood transfusion, hydroxyurea, and other medicines have primarily focused on managing symptoms and preventing complications
New Delhi: As traditional treatments such as blood transfusion, hydroxyurea, and other medicines have primarily focused on managing symptoms and preventing complications, experts on World Sickle Cell Day on Wednesday said that recent advancements in sickle cell anaemia and innovations in medical technology have led to the development of several promising new therapies.
According to Dr Meet Kumar, Clinical Director, Haematology & Bone Marrow Transplant, Marengo Asia Hospitals, Gurugram, clinical trials carried out gene editing as a potential treatment method for sickle cell disease.
As per preliminary findings, normal haemoglobin production may be enabled, which could significantly reduce sickle cell disease symptoms and effects.
As per experts, in sickle cell disease, the blood can get too thick and clot, causing various brain problems like silent strokes, regular strokes (both where blood flow is blocked and where there is bleeding), and other issues. This happens because the thick blood can block the blood vessels in the brain.
"Silent cerebral infarcts occur in about 40 per cent of children by 18 years. Headaches occur in about 36 per cent of children with sickle cell anaemia. Ischemic stroke occurs in about 10 per cent of children, and hemorrhagic stroke occurs in children at a rate of about 3-10 per cent," Dr Praveen Gupta, Principal Director & Chief of Neurology, Fortis Hospital, told IANS.
Sickle cell disease may affect the brain in various ways, including cognitive dysfunctions like working memory, verbal learning, visual motor function, inadequacy in general intellectual functioning, problems with language and attention, as well as headaches, seizures, and others, the experts noted.
Dr Gaurav Kharya, Founder and Director, Cellogen Therapeutics, said that gene therapy represents one of the most promising advancements in the treatment of sickle cell disease. This approach involves modifying the patient's own hematopoietic stem cells to correct the genetic defect responsible for the disease. He further mentioned that the modified stem cells are "then reintroduced into the patient's body".
"Early clinical trials have shown promising results, with some patients achieving significant improvements in symptoms and quality of life," Kharya added.
